Phase II trial of mitozolomide in patients with advanced ovarian cancer. A study of the EORTC Gynecological Cancer Cooperative Group.

Abstract

Twenty-seven fully evaluable patients with advanced ovarian cancer and documented disease progression despite cytotoxic treatment were treated with mitozolomide (NCS-353451) 90 mg/m2 as a 1-h infusion once every 6 weeks. None of the patients responded, one had stabilization of disease for 4 months. Haematologic toxicity was the major side effect with a nadir or white blood cell counts around day 40. Two patients died with severe leukopenia and septic shock. We conclude that mitozolomide is not active in this poor-risk group of patients.

• Authors: J P Neijt, M E van der Burg, J P Guastalla, M George, M Piccart, J Vermorken, F Carnino, N Rotmensz
• Journal: Acta oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 28 Issue 5 Pg. 663-5 ( 1989) ISSN: 0284-186X [Print] England
• PMID: 2590542 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Nitrogen Mustard Compounds
• mitozolomide

Topics

• Adult
• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Drug Evaluation
• Female
• Humans
• Middle Aged
• Nitrogen Mustard Compounds (adverse effects, therapeutic use)
• Ovarian Neoplasms (drug therapy, mortality)
• Survival Rate